MD492Y - Metodă de determinare a răspândirii cancerului gastric de tip intestinal - Google Patents

Metodă de determinare a răspândirii cancerului gastric de tip intestinal Download PDF

Info

Publication number
MD492Y
MD492Y MDS20110142A MDS20110142A MD492Y MD 492 Y MD492 Y MD 492Y MD S20110142 A MDS20110142 A MD S20110142A MD S20110142 A MDS20110142 A MD S20110142A MD 492 Y MD492 Y MD 492Y
Authority
MD
Moldova
Prior art keywords
gastric cancer
spread
determining
intestinal type
type gastric
Prior art date
Application number
MDS20110142A
Other languages
English (en)
Moldavian (mo)
Inventor
Lorena Mednicov
Ana Donscaia
Nicolae Ghidirim
Evghenia Samotiia
Original Assignee
Lorena Mednicov
Ana Donscaia
Nicolae Ghidirim
Evghenia Samotiia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lorena Mednicov, Ana Donscaia, Nicolae Ghidirim, Evghenia Samotiia filed Critical Lorena Mednicov
Priority to MDS20110142A priority Critical patent/MD492Z/ro
Publication of MD492Y publication Critical patent/MD492Y/ro
Publication of MD492Z publication Critical patent/MD492Z/ro

Links

Landscapes

  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Invenţia se referă la medicină, în special la oncologie şi poate fi utilizată pentru determinarea răspândiri cancerului gastric de tip intestinal.Conform invenţiei metoda constă în aceea că după stabilirea tipului de cancer gastric se efectuează analizele serologice şi se determină markerii CA 19-9, CA 125, antigenul carcinomului embrionar, gonadotropina corionică umană, numărul de T-limfocite citotoxice CD3 şi T-helperi CD4, în cazul, în care markerul CA 19-9 constituie 50,0…200,0 UI/ml, CA 125 - 35,0…500,0 UI/ml, antigenul carcinomului embrionar - 7,0…15,0 ng/ml, gonadotropina corionică umană - 18…287 ng/ml, T-limfocite citotoxice CD3 - 28…54%, iar T-helperi CD4 - 10…20%, se stabileşte răspândirea cancerului gastric de tip intestinal.
MDS20110142A 2011-08-17 2011-08-17 Metodă de determinare a răspândirii cancerului gastric de tip intestinal MD492Z (ro)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDS20110142A MD492Z (ro) 2011-08-17 2011-08-17 Metodă de determinare a răspândirii cancerului gastric de tip intestinal

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDS20110142A MD492Z (ro) 2011-08-17 2011-08-17 Metodă de determinare a răspândirii cancerului gastric de tip intestinal

Publications (2)

Publication Number Publication Date
MD492Y true MD492Y (ro) 2012-03-31
MD492Z MD492Z (ro) 2012-10-31

Family

ID=45929358

Family Applications (1)

Application Number Title Priority Date Filing Date
MDS20110142A MD492Z (ro) 2011-08-17 2011-08-17 Metodă de determinare a răspândirii cancerului gastric de tip intestinal

Country Status (1)

Country Link
MD (1) MD492Z (ro)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110484624B (zh) * 2019-08-28 2021-01-26 南京大学 一种基于外周血的胃癌生物标志物及其检测方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3222G2 (ro) * 2006-03-22 2007-08-31 Общественное Медико-Санитарное Учреждение Онкологический Институт Metodă de diagnostic al cancerului endometrial
MD3717G2 (ro) * 2008-03-21 2009-05-31 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Metodă de diagnostic diferenţiat al tumorilor glandei mamare
  • 2011

Also Published As

Publication number Publication date
MD492Z (ro) 2012-10-31

Similar Documents

Publication Publication Date Title
PH12019502484A1 (en) Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
PH12019500193A1 (en) Chimeric antigen receptors targeting bcma and methods of use thereof
CY1118668T1 (el) Ανοσοσυζευγματα εναντι υποδοχεα φολικου οξεος 1 και χρησεις αυτων
WO2019033043A3 (en) Anti-cd8 antibodies and uses thereof
CY1122161T1 (el) Συζευγμενα αντισωματα anti-cd38
CL2016002359A1 (es) Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco
NZ591882A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (gbm) and other cancers
MX2017014083A (es) Polipeptido de fusion anti-cancer.
CO2017001921A2 (es) Anticuerpos anti-cll-1 e inmunoconjugados
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
EP3885366A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
TN2017000203A1 (en) Antibodies against cd73 and uses thereof
PH12020550598A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
WO2015200828A8 (en) Conjugates for immunotherapy
MX2016007865A (es) Peptidos citotoxicos y conjugados de los mismos.
MY169147A (en) Drug-protein conjugates
WO2014008206A3 (en) DIAGNOSTIC AND THERAPEUTIC POTENTIAL OF HLA-E MONOSPECIFIC MONOCLONAL IgG ANTIBODIES DIRECTED AGAINST TUMOR CELL SURFACE AND SOLUBLE HLA-E
MX2021005085A (es) Formulacion de anticuerpo.
MX2019009121A (es) Antcuerpos anti-kaag1 o fragmento de union al antigeno del mismo para el tratamiento de cancer de mama triple negativo.
SG11201910113PA (en) Plasmin-cleavable anti-insoluble fibrin antibody-drug conjugate
WO2013170263A3 (en) Dosage and administration of bispecific scfv conjugates in combination with anti-cancer therapeutics
MD492Y (ro) Metodă de determinare a răspândirii cancerului gastric de tip intestinal
WO2016191703A3 (en) Tumor deliverable iron and protein synthesis inhibitors as a new class of drugs for the diagnosis and treatment of cancer
GB201100804D0 (en) Drug combination

Legal Events

Date Code Title Description
KA4Y Short-term patent lapsed due to non-payment of fees (with right of restoration)
MM4Y Short-term patent definitely lapsed due to non-payment of fees